Topline results from the SURPASS-CVOT trial reveal that once-weekly tirzepatide (Mounjaro) has a cardiovascular risk profile ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

According to expert presenters at the American Society of Preventive Cardiology’s 2025 Congress on Cardiovascular Disease Prevention, recent studies have shown significant benefit to GLP-1 inhibitors ...

An older woman with dementia and type 2 diabetes was started on semaglutide and subsequently developed severe psychological and physical symptoms, including apathy, significant weight loss and ...

A Phase III, international, randomized clinical trial assessed the safety and efficacy of canagliflozin for the treatment of ...

Q: I’m developing Parkinson’s disease. The symptoms are intermittent and mild, but I want to do everything I can to keep them that way. Can you let me know what ...